A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia

NCT07754799 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

320

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Daunorubicin
DRUG: Cytarabine
DRUG: Liposome Mitoxantrone
DRUG: Venetoclax
DRUG: Azacitidine
DRUG: Venetoclax
DRUG: Daunorubicin
DRUG: Cytarabine
DRUG: Venetoclax

Sponsor

Institute of Hematology & Blood Diseases Hospital, China